Chen et al. demonstrated that blocking Nrp1 using a monoclonal antibody inhibited the proliferation and migration of the human-derived glioma cell line U87MG and slowed tumor progression in vivo when the cell line was xenografted in mice [92]. Here, NRP1 is linked to central nervous system cancer.